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76 Poster Session IIntroduction: Cell dose is a critical factor influencing engraft-
ment and outcomes of cord blood (CB) transplantation. Rate of re-
jection is high (12–20%) in many pediatric non-malignant
disorders. Also, GVHD is not beneficial; 10–30% patients develop
acute GVHD $ grade II using bone marrow (BM) as the stem cell
source, while chronic GVHD occurs in 5–15% cases. During an
HLA-ID sibling donor (MSD)hematopoietic stem cell transplanta-
tion (HCT), the limited CB cell dose can be boosted by a BM har-
vest. We retrospectively studied the engraftment rate, incidence of
GVHD and outcomes of co-infusion of MSD CB and BM. Mate-
rials and Methods: 13 children underwent HCT after combining
CB and BM from their MSDs at multiple institutions between 6/
1998 to 6/2006. The data was collected from the Oakland Sibling
Cord Blood Registry database. Median age of patients was 5.9 years
(range: 2.2–13 yrs). HCT was performed for Thalassemia (n 5 7),
Sickle cell anemia (n 5 4), SAA and Hurler’s syndrome (1 each).
Most patients (9) received Busulfan, Cytoxan and ATG for condi-
tioning. The main reason for boosting CB with BM was a low
CD341 cell content in the CB unit. Median CB CD341 was 1.1
 105/kg (0.1–4.4  105/kg). The marrow cell dose ranged from
0.9  108/kg-2.6  108 TNC/kg recipient weight. Results: All 13
patients achieved donor engraftment. The median time to neutro-
phil recovery was 18 days (range: 12 to 27) and for platelet engraft-
ment was 29 days (range: 18 to 90). None of the patients developed
acute GVHD $ grade 2 and no chronic GVHD was reported.
There was no TRM and all patients remain alive with a median fol-
low-up of 1402 days (467–3406 days). None of the patients have re-
quired transfusions post-transplant and the patient with Hurler
syndrome has maintained 100% donor chimerism. Conclusions:
1. There were no engraftment failures after co-infusion compared
to the higher historical rates reported after HCT using BM or
CB alone in non-malignant conditions.
2. The addition of BM to boost the cellular content promoted rapid
engraftment. There was a more rapid rate of recovery of neutro-
phils and platelets particularly, compared to conventional CB
transplantation, which might have reduced TRM.
3. No acute or chronic GVHD was noted after co-infusion inspite
of increased cell dose. Combining CB to BMmay have mitigated
the risk of GVHD.
4. Co-infusion of BM and CB is a feasible and effective strategy in
improving outcomes of HCT in non-malignant disorders, when
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LOW MOLECULAR WEIGHT HEPARIN (LMWH) PROPHYLAXIS (PPX) IN
PEDIATRIC RECIPIENTS FOLLOWING PEDIATRIC MYELOABLATIVE
STEM CELL TRANSPLANT (SCT) AT HIGH RISK FOR SINUSOIDAL OB-
STRUCTIVE SYNDROME (SOS): IS IT SAFE AND DOES IT MAKE A DIFFER-
ENCE?
Rogoza, K.1, Bhatia, M.2, Baldinger, L.1, van de Ven, C.2, Militano, O.1,
Qualter, E.1, Cairo, M.S.2. 1Morgan Stanley’s Children’s Hospital of
NewYork-Presbyterian, New York, NY; 2Columbia University, New
York, NY.
SOS is a clinical syndrome following SCTof jaundice, painful he-
patomegaly and weight gain with an incidence of 20% (2–54%) and
a mortality rate of 30–50%. The Children’s Group reported a 10%
incidence of SOS in pediatric recipients (n 5 2725; mild:3.1%,
moderate:5.2%, severe:2%) with a 1.8% mortality rate (Neider,
ASBMT, 2007). Risk factors include hepatitis, transaminitis, he-
patic irradiation, second SCT, and myeloablative conditioning reg-
imens (busulfan .8 mg/kg, cyclophosphamide $120 mg/kg, TBI,
and/or melphalan$135 mg/m2). We have demonstrated the safety
and efficacy of unfractionated heparin for SOS PPX in pediatric
SCT recipients (Rosenthal/Cairo et al, BMT, 1996). Simon et al
(BMT, 2001) demonstrated the use of LMWH for SOS PPX in
adult recipients. In this study we investigated the use of LMWH
in patients (pts) at high risk ($ 2 risk factors) for SOS to determine
if there was a difference in incidence of SOS compared with stan-
dard risk recipients not receiving LMWH. 36 pts at very high risk
for SOS received LMWH (1 mg/kg SQ) from 1st day of condition-
ing until D 1 21 post SCT. Median age 8.1 years (0.3–21, 23M/13F). Anti-Factor Xa levels were maintained between 0.3–0.5 Iu/
ml. Platelets were kept .30,000/mm3. Hemorrhage was graded
by NCI CTCAE 3.0. SOS was graded according to McDonald cri-
teria (Ann Int, 1993). 52 pts with\2 risk factors did not receive
LMWH PPX. Median age 8.6 years (0.3–23, 26M/26F). Of those
receiving LMWH, 4 pts developed SOS (mild, n 5 1; moderate,
n5 1; severe, n5 2). There were no hemorrhagic Grade III/IV tox-
icities. In the comparative standard risk group, 2 pts developed
moderate SOS. The probability of developing SOS in the high-
risk LMWH vs. comparison group was not significantly different:
11.1% (CI 95: 0.8–21.4) vs. 3.8%(CI95: 0–9.1), p 5 0.17 (Fig 1).
The OS in the LMWH group (50.3%) vs. the comparison standard
risk group (49.4%) was not statistically significant. No significant
difference in OS was observed in each sub-group who developed
SOS. These results suggest that LMWH can be administered safely
and may be effective SOS PPX in very high-risk pediatric SCT re-
cipients. A randomized double blind international trial comparing
LMWH vs. placebo will be required to determine the efficacy of
LMWH in pediatric SCT recipients at high risk of post SCT
SOS.206
FLUCTUATIONS IN CD31 SUBSET CHIMERISM ARE NOT PREDICTIVE OF
GRAFT REJECTION IN CHILDREN UNDERGOING TRANSPLANT FOR NON-
MALIGNANT DISORDERS
Ozyurek, E.1, Cowan, M.2, Koerper, M.2, Baxter-Lowe, L.A.3, Horn, B.2.
1Ondokuz University, Samsun, Turkey; 2University of California San
Francisco, San Francisco, CA; 3University of California San Francisco,
San Francisco, CA.
In non-malignant disorders, complete donor hematopoietic chi-
merism is not required for reversal or cure of underlying disease.
However, the risk of graft rejection may correlate with the degree
of donor chimerism.We postulated that the degree of donor chime-
rism, in particular, in CD31 cell lineage, may predict durability of
engraftment.
Retrospective chimerism data from 25 children undergoing 1st
transplant at UCSF between 2001 and 2007 were analyzed. The di-
agnoses included: bone marrow failure syndromes (N 5 9); meta-
bolic disorders (N 5 7); immunodeficiencies (N 5 6);
hemoglobinopathies (N 5 2); and autoimmune disorders (N 5 1).
Prevalence of GvHD
100 days (n 5 37*) 1 yr (n 5 32*) Latest F/U (n 5 18*)
Donor type Related Unrelated Related Unrelated Related Unrelated
Grade 2-4
AGvHD
4/16 (25%)2/21 (10%)1/15 (7%) 1/17 (6%)
Extensive
CGvHD
2/15 (13%)2/17 (12%) 3/8 (38%) 0/10 (0%)a
*n 5 Number of patients alive at day 100, alive at 1 yr and alive at
latest F/U which is longer than 1 yr after HSCT.
aFor related vs. unrelated, Fisher’s exact p 5 0.069. All other com-
parisons not significant with p . 0.1.
Poster Session I 77Twelve patients received a matched unrelated donor transplant, and
13 received a matched related donor transplant. Conditioning in-
cluded 1 of these 3 regimens: Busulfan, Fludarabine, and Alemtuza-
mab or rATG (N5 19); Busulfan, Cyclophospamide and ATG (N
5 2); or Cyclophosphamide and rATG (N5 4). Percent donor en-
graftment in the CD31 subset and whole blood chimerism
(WhBCh) was determined using short tandem repeats. Testing
started around day 130, and it was repeated every 2–4 weeks until
stable CD31 and WhBCh was achieved. Median follow up for liv-
ing patients was 16 mos (4–62 mos).
All patients initially engrafted.We observed 6 chimerismpatterns
as shown in Table 1. Seventeen patients (68%) remained mixed chi-
mera for the duration of follow-up. A majority of patients (71%)
with mixed chimerism had either very low (\20%) or fluctuating
CD31 cell chimerism. One of four patients with declining
WhBCh, discordant with slowly increasing CD31 chimerism, de-
veloped late graft failure at 8months post transplant, and underwent
a 2nd transplant. Both patients with a precipitous decline in CD31
andWhBCh rejected their grafts by 2 months post transplant. This
was the only pattern predictive of graft rejection. Low percentage or
fluctuations in donor CD31 chimerism, in light of stable WhBCh,
were not predictive of graft rejection or clinical outcome.207
OCCURRENCE OF GRAFT VERSUS HOST DISEASE AFTER HEMATOPOI-
ETIC STEM CELL TRANSPLANT UTILIZING REDUCED INTENSITY CONDI-
TIONING IN PEDIATRIC PATIENTS
Danner-Koptik, K.1, Fu, J.3, Dilley, K.J.1,2. 1Children’s Memorial Hos-
pital, Chicago, IL; 2Northwestern University, Chicago, IL; 3The Ohio
State University, Columbus, OH.
Background: Reduced intensity conditioning (RIC) regimens
are used as an alternative to traditional myeloablative conditioning
(TMC) for allogeneic hematopoietic stem cell transplant (HSCT)
in children. The main rationale is to allow tumor kill while decreas-
ing the degree of toxicity due to conditioning regimen.Objective:
To examine the occurrence of acute (A) and chronic (C) GvHD in
pediatric patients who received a RIC HSCT. Methods: Medical
record review of all patients who received a RIC HSCT from
2000 to the present at a single institution. Patients who ever re-
ceived a TMC HSCT or who had .1 RIC HSCT were excluded.
AGvHD data was collected at 100 days and 1 year; CGvHDwas ex-
amined at 1 yr and latest follow-up (F/U). Results: Since 2000, 86
pediatric patients have undergone RIC HSCT for both malignant
(55%) and non-malignant (45%) diseases. 57% were male. All pa-
tients received a common backbone for conditioning including flu-
darabine and busulfan, plus or minus ATG or extracorporeal
photopheresis. At analysis, 27 patients were excluded for having re-
ceived a TMC HSCT and 15 more were excluded for .1 RIC
HSCT, with 44 patients who received a single RICHCST included
in all further analyses. 17/44 (39%) transplants had related donor
peripheral blood stem cells as a donor source (related), which are
subsequently compared to all other sources (unrelated). Related do-
nor transplants were done at recipient mean age 7.8 yr vs unrelated
9.2 yr (p5 0.45). 68% of patients analyzed are currently alive, 18/44
(41%) alive at.1 yr from HSCT. GvHD was seen at the examined
timepoints in 23% (10/44) of patients overall, with 14% (6/44) hav-
ing AGvHD only, 11% (5/44) CGvHD only and 9% (4/44) experi-
encing both. No differences were found in occurrence of grade 2–4
AGvHD or extensive CGvHD at examined timepoints when com-
paring donors, except a trend toward more AGvHD at 100 days and
more CGvHD at latest F/U for related donors (see table).Conclu-
sion: It has been hypothesized that a RIC regimen will lead to less
recipient tissue damage with less inflammatory cytokine release and
may result in fewer toxicities and less GvHD. In pediatric RIC
HSCT we demonstrate a low prevalence of grade 2–4 acute and ex-
tensive chronic GvHD during a short F/U period, with no statisti-
cally significant differences between related and unrelated donor
stem cell sources. Future study with case-matched controls receiv-
ing TMC HSCT will help determine whether toxicity and GvHD
are reduced in RIC HSCT.208
THE USE, SAFETY, AND EFFICACY OF DACLIZUMAB FOR STEROID RE-
FRACTORY GRAFT-VERSUS-HOST-DISEASE (GVHD) AFTER UNRELATED
CORD BLOOD TRANSPLANTATION (UCBT)
Mohamed, A.1, Niedzwiecki, D.2, Baker, J.H.1, Vinesett, R.1,
Martin, P.L.1, Driscoll, T.A.1, Prasad, V.K.1, Parikh, S.1,
Kurtzberg, J.1, Szabolcs, P.1. 1Duke University, Durham, NC; 2Duke
University, Durham, NC.
UCBT is a life-saving form of hematopoietic cell transplantation
(HCT), however GVHD can hamper success. Steroid refractory
GVHD increases the incidence and severity of infections, leads to in-
creasedmortality by 6months.Daclizumab, a humanized anti-CD25
antibody has been widely utilized for treatingGVHD after favorable
reports (Blood 1994;84:1320, Blood 2000;95:83). It’s efficacy and
safety, however, has been questioned by a recentmulticenter, double
blinded, randomized trial (Blood;2004:104:1559) showing inferior
100-day and 1 year survival. The efficacy and safety of daclizumab af-
terUCBT,however is not known.We report here the results of a ret-
rospective analysis on a cohort of three hundred twenty nine (329)
children who received a single UCB graft as first transplant between
1999 and 2005. All received myeloablative conditioning regimens,
ATGpre-UCBTandGvHDprophylaxis consistingofCyclosporine
1Methylprednisolone (MPDN) or MMF (last 12 pts).
Results:Daclizumab was used to treat steroid refractory GVHD
in 89 patients (27%). 58 patients started therapy at a median of 36
days (mean 366 19) post-UCBT for acuteGVHD, while 31 started
significantly later at a median of 207 days (mean 3866 452). Those
who received Daclizumab for acute GVHD (n5 58) were analyzed
and compared to the 239 patients who never received the drug (most
with grade 0-I GVHD). In univariate analysis, patients receiving
Daclizumab were significantly younger (mean 5.1 vs 6.9 years, p
5 0.03), less likely to have malignancy (p 5 0.001) and received
TBI (p 5 0.004). There were no differences in gender, ethnicity,
CMV serology, HLA-mismatch, TNC, CD31, and CD341 cell
dose/kg. OS at 6 months was comparable between these groups,
(57% versus 65% Chi-Square p 5 0.23). After 42 days of therapy,
response was scored based on IBMTR consensus criteria. 10 pa-
tients did not complete therapy due to death in 9; [relapse (3),
pre-existing infections (4), multiorgan failure (2)] Of those evalu-
able at D42, overall GVHD severity was downgraded in 35 of 46
(76%). MPDN was reduced from a mean of 2.0 mg/kg/day to
0.90 mg/kg/day by D42. Skin GVHD was downgraded to stage
0–1 in 45 of 46 patients. 11 patients with gut GVHD stages 2–4 im-
proved to stage 0–1 while 8 either failed to respond or worsened to
$stage 2. None of the three patients with liver GVHD (stages 3–4)
responded. Conclusion: Daclizumab therapy in UCBT recipients
appears safe with excellent response in skin but modest response
for visceral GVHD.
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UMBILICAL CORD BLOOD STEM CELL TRANSPLANTS FOR NONMALIG-
NANT HEMATOPOIETIC DISORDERS
Willert, J.1, Rosenthal, J.2, Brown, H.L.3, David, H.T.4. 1Rady Chilren’s
Hospital of San Diego, San Diego, CA; 2City of Hope, Duarte, CA; 3CBR
Systems, Inc., San Bruno, CA; 4University of Arizona, Tucson, AZ.
